HMGA and cancer.

HMGB1 in health and disease. Mol Aspects Med (2014) 1.67

Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. Nat Rev Cancer (2012) 1.45

CBX7 is a tumor suppressor in mice and humans. J Clin Invest (2012) 1.24

An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis. Dev Cell (2012) 1.10

Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol (2012) 1.07

HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. Oncotarget (2014) 1.00

High mobility group a proteins as tumor markers. Front Med (Lausanne) (2015) 0.99

HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia (2013) 0.92

Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes. Oncotarget (2015) 0.90

Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89

The Wnt/β-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer. Cell Biochem Funct (2012) 0.87

High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer (2014) 0.87

HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Virchows Arch (2012) 0.86

Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo. J Biol Chem (2010) 0.86

Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. Cancer Res (2013) 0.85

TLX1 and NOTCH coregulate transcription in T cell acute lymphoblastic leukemia cells. Mol Cancer (2010) 0.85

Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer. Oncotarget (2015) 0.85

Cross-linking of DNA through HMGA1 suggests a DNA scaffold. Nucleic Acids Res (2011) 0.84

MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer. Int J Clin Exp Pathol (2015) 0.84

Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice. Biochem Biophys Res Commun (2013) 0.84

HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma. Oncotarget (2016) 0.82

The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity. J Neuropathol Exp Neurol (2015) 0.81

Cis-regulation of microRNA expression by scaffold/matrix-attachment regions. Nucleic Acids Res (2011) 0.81

CBX7 gene expression plays a negative role in adipocyte cell growth and differentiation. Biol Open (2014) 0.81

The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett (2016) 0.81

Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas. Front Med (Lausanne) (2015) 0.80

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma-differences in histological subtypes. BMC Cancer (2016) 0.77

High Mobility Group A2 protects cancer cells against telomere dysfunction. Oncotarget (2016) 0.77

Do short, frequent DNA sequence motifs mould the epigenome? Nat Rev Mol Cell Biol (2016) 0.77

The association between S100A13 and HMGA1 in the modulation of thyroid cancer proliferation and invasion. J Transl Med (2016) 0.77

Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer. Mol Cell Proteomics (2015) 0.77

Transcriptional regulation of the HMGA1 gene by octamer-binding proteins Oct-1 and Oct-2. PLoS One (2013) 0.76

HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. Neoplasia (2016) 0.76

History of uterine leiomyoma and risk of endometrial cancer in black women. Cancer Causes Control (2016) 0.75

High Mobility Group A proteins in esophageal carcinomas. Cell Cycle (2016) 0.75

Expression and functional characterization of Xhmg-at-hook genes in Xenopus laevis. PLoS One (2013) 0.75

Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. J Neurooncol (2017) 0.75

HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation. Am J Cancer Res (2017) 0.75

Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I. Nucleic Acids Res (2016) 0.75

HMGA2 expression distinguishes between different types of postpubertal testicular germ cell tumour. J Pathol Clin Res (2015) 0.75

GSK3β activity is essential for senescence-associated heterochromatin foci (SAHF) formation induced by HMGA2 in WI38 cells. Am J Transl Res (2017) 0.75

Molecular characterization of the t(4;12)(q27~28;q14~15) chromosomal rearrangement in lipoma. Oncol Lett (2016) 0.75

IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1. Elife (2017) 0.75

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med (2002) 4.69

MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer (2007) 3.53

Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 3.33

DNA damage, homology-directed repair, and DNA methylation. PLoS Genet (2007) 2.29

Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett (2004) 2.17

Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res (2005) 2.10

Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09

Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA (2011) 2.00

Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene (2002) 1.99

RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab (2006) 1.98

HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell (2006) 1.96

Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat Med (2005) 1.64

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene (2004) 1.63

Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene (2005) 1.53

Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch Gen Psychiatry (2010) 1.49

A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res (2007) 1.47

The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol (2004) 1.43

Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab (2004) 1.36

Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res (2006) 1.34

Retracted High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest (2007) 1.34

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol (2006) 1.29

Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res (2008) 1.28

MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab (2011) 1.28

Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle (2003) 1.25

Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res (2009) 1.25

CBX7 is a tumor suppressor in mice and humans. J Clin Invest (2012) 1.24

HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res (2004) 1.23

Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer (2010) 1.21

Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol (2003) 1.20

Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis (2005) 1.18

Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol (2005) 1.18

Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci (2002) 1.17

Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer (2010) 1.16

HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res (2009) 1.16

Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab (2012) 1.15

The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer (2010) 1.15

Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene (2004) 1.14

HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer (2008) 1.14

Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. Genes Cancer (2010) 1.13

TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res (2006) 1.12

TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer (2010) 1.12

Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab (2002) 1.12

The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res (2009) 1.11

HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene (2002) 1.11

HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology (2012) 1.11

Regulation of BRCA1 transcription by specific single-stranded DNA binding factors. Mol Cell Biol (2003) 1.10

Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell Cycle (2004) 1.10

UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer (2007) 1.10

Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab (2012) 1.08

The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. Oncogene (2005) 1.08

The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene (2004) 1.08

HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07

Minireview: RET: normal and abnormal functions. Endocrinology (2004) 1.06

HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell (2012) 1.05

High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. Cancer Res (2010) 1.04

The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. BMC Biol (2009) 1.04

miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. J Clin Endocrinol Metab (2011) 1.03

FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer (2007) 1.03

Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene (2002) 1.03

Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J (2003) 1.02

The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. Mol Oncol (2013) 1.02

Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid (2011) 1.01

Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis (2004) 1.00

Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J (2007) 1.00

HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. Oncotarget (2014) 1.00

Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. DNA Cell Biol (2006) 0.99

Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene (2005) 0.99

An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res (2003) 0.99

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res (2006) 0.98

A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer (2013) 0.96

RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res (2007) 0.96

RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab (2002) 0.95

Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol (2002) 0.95

Retracted POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation. J Biol Chem (2012) 0.95

The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res (2002) 0.94

TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. J Clin Endocrinol Metab (2011) 0.94

Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. Mol Biol Cell (2003) 0.94

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab (2003) 0.94

PATZ attenuates the RNF4-mediated enhancement of androgen receptor-dependent transcription. J Biol Chem (2001) 0.94

High-mobility group A1 proteins are overexpressed in human leukaemias. Biochem J (2003) 0.93

Retracted Targeted disruption of the murine homeodomain-interacting protein kinase-2 causes growth deficiency in vivo and cell cycle arrest in vitro. DNA Cell Biol (2009) 0.93

Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle (2006) 0.93

The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab (2002) 0.93

Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocr Relat Cancer (2010) 0.93

The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem Biophys Res Commun (2002) 0.93

Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene (2004) 0.92

Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Ther (2004) 0.92

HMGA2: A pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol (2010) 0.92

Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol (2003) 0.92

A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas. Carcinogenesis (2003) 0.91

Diagnostic significance of high mobility group I(Y) protein expression in intraductal papillary mucinous tumors of the pancreas. Pancreas (2002) 0.91

Identification of the genes up- and down-regulated by the high mobility group A1 (HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. Cancer Res (2004) 0.91

High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. J Cell Physiol (2014) 0.91

HMGA1 protein expression in familial breast carcinoma patients. Eur J Cancer (2009) 0.91

UbcH10 expression in human lymphomas. Histopathology (2009) 0.91

Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab (2011) 0.91

Thyrotropin regulates thyroid cell proliferation by up-regulating miR-23b and miR-29b that target SMAD3. J Clin Endocrinol Metab (2012) 0.91

Embryonic defects and growth alteration in mice with homozygous disruption of the Patz1 gene. J Cell Physiol (2013) 0.90